#Obesity medicine
Chronic weight management as a clinical specialty.
GLP-1 Agonists in Older Adults: Key Issues
Sarcopenia, polypharmacy, and limited age-specific data shape GLP-1 receptor agonist use in older adults with obesity and type 2 diabetes.
MASH drugs: resmetirom and semaglutide
Resmetirom and semaglutide now hold conditional approvals for MASH. Here is what the trial evidence shows and where gaps remain.
Real-world semaglutide: dose and dropout
A Danish study of 206 patients found 38% permanently stopped semaglutide within 12 months; 70% of continuers used doses below the 2.4 mg approved maximum.
SURMOUNT-OSA post-hoc: who benefits most
SURMOUNT-OSA post-hoc (Sleep, 2026): more-symptomatic patients saw larger subjective gains; objective AHI and weight changes were consistent across subgroups.
GLP-1 drugs in pediatric obesity
Liraglutide and semaglutide carry regulatory approval for adolescents with obesity. A 2026 review maps what the trials found and what gaps remain.
Semaglutide side effects: what trials show
The STEP and SUSTAIN programmes documented semaglutide adverse events at scale. Here is what the data show, from GI effects to the thyroid boxed warning.
Sex differences in semaglutide muscle loss
A July 2026 study finds female ob/ob mice are protected from semaglutide-induced muscle loss while males are not. What the finding means and what it does not.
Tirzepatide, CAVI, and arterial stiffness
A 2026 retrospective cohort found tirzepatide reduced CAVI from borderline to normal, alongside weight loss and glycaemic improvements, over 12.7 months.
Dapagliflozin plus semaglutide: BMI classes
A 328-patient Saudi cohort: proportional BMI response to dapagliflozin is uniform across obesity classes; semaglutide add-on helps most in class I.
GLP-1 drugs and micronutrient risk
How GLP-1 receptor agonists and dual incretin drugs create vitamin and mineral gaps, which nutrients are most at risk, and what monitoring looks like.
Incretins after bariatric surgery
A US cohort of 208,155 post-bariatric patients: tirzepatide beat semaglutide on weight loss (17.2% vs 12.0%). No significant cardiovascular signal either way.
Orforglipron for sleep apnea: ATTAIN-OSA
ATTAIN-OSA is testing an oral GLP-1 pill against sleep apnea. Here is what the 712-participant protocol measures and how it compares to SURMOUNT-OSA.